| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis |
|
Medicine details |
|
| Medicine name | vutrisiran (Amvuttra®) |
| Formulation | Subcutaneous injection |
| Reference number | 5076 |
| Indication | Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. |
| Company | Alnylam Pharmaceuticals Inc |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/09/2022 |
| NICE guidance | TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis |